Authors
Latest:
Using Comprehensive Genomic Profiling to Identify Rare Subsets of Merkel Cell CarcinomaRyan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Latest:
EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung CancerIn this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.
Latest:
SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 MutationsA blood cancer specialist discusses the latest data from the SEQUOIA Arm D trial investigating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.
Latest:
Integrating Physician Opinions Into DLBCL Treatment SelectionPatrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma
Latest:
T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer Supported by Subgroup AnalysisFam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.
Latest:
Exploring the Need for Second-Line Treatments in Thyroid CancerCesar Augusto Perez, MD, discusses one of the top unmet needs that exists in the thyroid cancer space.
Latest:
About the C-800 Trial of Botensilimab/Balstilimab in Ovarian CancerBruno Bockorny, MD, discusses the phase 1 C-800 trial of botensilimab plus bastilimab, specifically for patients in the C-800-01 cohort with recurrent platinum refractory/resistant ovarian cancer.
Latest:
Leukemia Awareness Month: Changing the Future of AML through Precision MedicineGwen Nichols, MD, reviews the evolving landscape of acute myeloid leukemia for Leukemia Awareness Month.
Latest:
Genetic Risk Score Revolutionizes TNBC Prediction in Black WomenHolly Pederson, MD, and Elisha Hughes, PhD, discuss the findings and implications of a study evaluating risk of triple-negative breast cancer for Black women presented at the 2024 ASCO Annual Meeting.
Latest:
An Update on Current and Emergent Therapies for Essential ThrombocytosisThe therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.
Latest:
Handling GI Toxicities While Using Selinexor Triplet Therapy in RRMMAdam Binder, MD, discusses how to handle gastrointestinal toxicities for patients with relapsed/refractory multiple myeloma who are on the triple therapy of selinexor, bortezomib, and dexamethasone.
Latest:
Imetelstat and Canakinumab in Lower-Risk MDSDrs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.
Latest:
Dysphagia-Optimized IMRT Shows Significance in Head and Neck CancerChristopher Nutting, MD, discusses the results of a randomized phase 3 trial using dysphagia-optimized intensity modulated radiotherapy versus standard IMRT in patients with head and neck cancer.
Latest:
Role of Ruxolitinib in GVHD TreatmentDrs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.
Latest:
Clinical Considerations with Axtilimab in R/R GVHDPanelists discuss how clinical considerations shape the use of axatilimab in relapsed or refractory graft-versus-host disease, addressing factors that influence its application and management in practice.
Latest:
Dostarlimab's Promise in dMMR Locally Advanced Rectal CancerMark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair-deficient rectal cancer about the potential for long-term disease control with this agent.
Latest:
Tumor-Infiltrating Lymphocytes: Rationale for Use in the Treatment of Solid Tumors and Potential Benefits and DrawbacksIn the second interview of this series, Ben Creelan, MD, Associate Member at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.
Latest:
The Future of Treating Small Cell Lung CancerKartik Konduri, MD, comments on the future of treating extensive-stage small cell lung cancer and provides advice for community oncologists treating patients with the disease.
Latest:
Triple Therapy Demonstrates Early Activity in Refractory MyelomaA novel, all-oral combination regimen of mezigdomide, tazemetostat, and dexamethasone demonstrated early signals of activity and a tolerable safety profile in patients with highly refractory multiple myeloma.
Latest:
Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.
Latest:
Findings of the IMMUTACE Trial in Hepatocellular CarcinomaArndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.
Latest:
Analysis Explores Impact of Increased Point Mutations With High-Dose Melphalan in MyelomaMehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.
Latest:
Considering Unmet Needs of Premenopausal Patients With Breast CancerYeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.
Latest:
About the Continued Evaluation of MK-1084 for NSCLC and MoreCarlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Latest:
Quality of Life Considered When Starting Treatment in MDSMikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.
Latest:
Whether Telehealth or In Person, Palliative Care Offer Benefits for Patients With Advanced Lung CancerJoseph Greer, PhD, discusses the late-breaking abstract from the 2024 ASCO Annual Meeting evaluating telehealth vs in-person palliative care for patients with advanced non-small cell lung cancer.
Latest:
Evaluating Ways of Measuring MRD in Hematologic MalignanciesJerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.
Latest:
Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare CancersThe study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.
Latest:
The Gut Microbiome and Immunotherapy: New Research Explores CBM588's Mechanism in mRCCHedyeh Ebrahimi, MD, MPH, discusses a study that found adding the live bacterial product CBM588 to standard immunotherapy potentially impacted patients' responses in renal cell carcinoma.
